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ABSTRACT 
 
 
 
 
Haematopoiesis is a term that describes the formation of mature cellular blood 
components from haemopoietic progenitor stem cells (HPC). The majority of HPC 
reside in the bone marrow (BM) with a small number continually escaping into the 
circulation then re-homing back into the BM in a process called trafficking. Stromal 
cells in the BM constitutively express and secrete stromal cell derived factor (SDF-1). 
This highly conserved chemokine binds to heparin and to CXCR4 receptor acting as a 
chemo-attractant for CXCR4+ cells; the system plays a role in regulating stem cell 
trafficking. 
 
This study examined the clinical effects of ingesting fucoidan extracted from brown 
macro-algae (Undaria pinnatifida) in vitro and in vivo in a series of single blinded 
placebo-controlled clinical trials. Fucoidans comprise sulphated long branched chains 
of sugar, containing large amounts of fucose and galactose. Fucoidan is biologically 
active and is known to modulate coagulation, inflammation, cell proliferation and 
adhesion, tumorigenesis and resistance to viral infection. To study its clinical value an 
ELISA assay based on a novel antibody was established to quantify the level of the 
bio-available fucoidan in human plasma after oral doses. The consequences of 
ingesting fucoidan on healthy volunteers were investigated in detail by studying 
different biological and pathological parameters including liver and kidney functions.  
 
This study established that daily ingestion of 3 g of different fucoidan extracts for 2 
weeks is safe. To study the anticoagulant activity of fucoidan, haemostasis was 
examined closely in vitro and in vivo. Although, fucoidan is a highly potent 
anticoagulant in vitro there was limited activity when used orally. Fucoidan was found 
also to positively regulate the lipid profile by reducing cholesterol and triglyceride 
plasma levels. The effect of fucoidan on HSPC trafficking was tested. Ingestion of 
fucoidan increased the expression of CXCR4 on CD34+ cells and increased the plasma 
level of SDF-1 and IFN-γ. A decrease in CD4+ and CD8+ cells was also observed in 
volunteers who ingested fucoidan. When either peripheral blood or cord blood CD34+ 
cells were cultured in vitro in a cytokine expansion system CXCR4 on CD34+ cells 
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was down-regulated. This study also showed that fucoidan slows down the CD34+ cell 
cycle and interacts and binds with different cytokines (SCF, TPO, Flt-3 and SDF-1) 
and presents them to cells. In conclusion, this study showed that fucoidan has several 
clinical effects including effects on lipids regulation, haemostasis, immune system, 
haematopoiesis, trafficking of HSPC and related cytokines.  
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